Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Combination With PD-1 Inhibitor in Patients With HER2-Related Advanced Solid Tumors

NCT07698587 is registered in ClinicalTrials.gov with Suzhou Biomissile Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07698587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07698587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BM230 in Combination With PD-1 Inhibitor in Patients With HER2-Related Advanced Solid Tumors
Lead sponsor
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2029
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor